What the publication found
The 2025 SURMOUNT-5 randomized trial compared tirzepatide with semaglutide in 751 adults with obesity who did not have type 2 diabetes. At 72 weeks, mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide at the maximum tolerated study doses. That is a difference of 6.5 percentage points of initial body weight. Gastrointestinal adverse events were the most common in both groups, were mostly mild or moderate, and occurred primarily during dose escalation. Source: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
What the evidence cannot establish
The trial was open-label, meaning treatment assignment was known, and was funded by Eli Lilly. These averages are not individual forecasts. The findings apply to the studied population, products, dosing approach, and follow-up period; they do not establish equivalent results for compounded preparations or everyone seeking weight care. A larger average weight change alone does not determine which treatment is suitable for a person. Source: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Read percentages with the denominator in mind
In this trial, the percentages describe change from initial body weight. The difference between the reported averages is a percentage-point difference, not the percentage of patients who succeeded. Before comparing headlines, check whether they describe average change, the proportion meeting a threshold, or another outcome. Ask which measure would be relevant to your own goals.
Compare the whole care plan
A consultation can address more than an average trial result. Bring questions about suitability, tolerability, follow-up, access, total costs, and how progress will be assessed. Ask what would happen if the proposed approach did not fit your needs. A clear plan should make the next review and the reasons for reassessing understandable before treatment begins.
Using the evidence in Palatine
Bring a medication list and a record of previous weight-care approaches to your visit. Our Palatine clinic is at 600 N North Ct, Suite 120. This research summary is not a quote for medication, a guarantee of prescribing, or confirmation of insurance coverage. Ask about the exact product being discussed and whether the cited trial directly applies to it.
Questions to bring to your visit
- How closely do I resemble the population studied?
- Which product is being proposed, and is this trial relevant to it?
- What benefits, adverse effects, costs, and follow-up should shape the decision?
Sources and further reading
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.Journal publication · Peer-reviewed randomized trial. 2025
This is a patient-facing guide, not an original research publication. Prepared with AI assistance and checked against the linked sources. No clinician review is claimed. General education cannot determine which care is right for you.